Rizwana F. Sproule, VP Regulatory Affairs at Kite Pharma, Inc. (KITE), sold 9,567 shares at $76.46 ($748K) on 2015-11-16, disclosed to the SEC on 2015-11-18.
Scheduled sale ($748k) by VP Regulatory Affairs under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $76.46 | 1,424 | $109K | 14.6% |
| 2 | $77.62 | 1,791 | $139K | 18.6% |
| 3 | $78.49 | 5,236 | $411K | 55.0% |
| 4 | $79.27 | 944 | $75K | 10.0% |
| 5 | $80.27 | 172 | $14K | 1.8% |
| Total | $78.13 avg | 9,567 |
| $748K |
| 100% |
| Filing → |
| KITE | SELL | 2016-01-19 | $531K | — | Filing → |
| KITE | SELL | 2015-12-17 | $610K | — | Filing → |
| KITE | SELL | 2015-10-19 | $599K | — | Filing → |